Analytical Method Validation for Estimation of Neurotransmitters (Biogenic Monoamines) from Cerebrospinal Fluid Using...

Area of Science:

• Neuroscience
• Clinical Chemistry
• Biochemistry

Background:

• Biogenic amine neurotransmitters, including serotonin and dopamine, are crucial for nervous system signaling.
• Metabolic defects in these neurotransmitters lead to altered levels of key metabolites: 5-Hydroxyindole acetic acid (5HIAA), homovanillic acid (HVA), and 3-O-Methyl Dopa (3-OMD).
• Accurate estimation of these CSF metabolites is vital for diagnosing neurotransmitter-related disorders but is technically challenging and often limited to specialized centers.

Purpose of the Study:

• To optimize and validate a high-performance liquid chromatography (HPLC) method for the simultaneous analysis of 5HIAA, HVA, and 3-OMD in cerebrospinal fluid (CSF).
• To establish a reliable and accessible method for quantifying these neurotransmitter metabolites, facilitating broader clinical application.

Main Methods:

• A high-performance liquid chromatography (HPLC) system coupled with an electrochemical detector (ECD) was employed.
• The method underwent rigorous validation, including linearity assessment, quality control analysis, and external proficiency testing.
• Reference ranges were verified, and clinical correlation studies were performed on patient samples.

Main Results:

• The method demonstrated excellent linearity for 5-HIAA (65.35-2615.0 nmol/L), HVA (68.62-2745.0 nmol/L), and 3-OMD (236.5-4730.0 nmol/L).
• Internal quality controls showed coefficients of variation ranging from 5% to 14%, and external proficiency testing results were within acceptable peer group ranges.
• Analysis of 40 suspected patients identified four individuals with confirmed neurotransmitter defects, validated by molecular testing and clinical correlation.

Conclusions:

• The developed HPLC-ECD method is validated for the accurate and reliable quantification of 5HIAA, HVA, and 3-OMD in CSF.
• This optimized method can be adapted by clinical laboratories with appropriate HPLC expertise, improving the diagnosis of neurotransmitter defects.
• The findings support the use of this method for routine clinical testing and diagnosis of neurological disorders associated with altered biogenic amine metabolism.